largeArtboard 1-100.jpg
 
 
 
 
 

About Us

 

Transforming drug discovery

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.

 
ATOM mission circles.png
 
 

History

In June 2016, GSK, the Department of Energy, and the National Cancer Institute announced their intent to create the ATOM partnership as one of the Cancer Moonshot task forces, with funding support under the 21st Century Cures Act.

The ATOM Consortium was officially established in October 2017.

ATOM founding members are GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. 

 
21st Century Cures logo small.png

The goals of ATOM are tightly aligned with those of the 21st Century Cures Act, which aims in part to enable a greater number of therapies to reach more patients more quickly.
— David Heimbrook, Laboratory Director at FNLCR

 

Vision

Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.

 
ATOM target to patient-ready.png
 

ATOM is a novel public-private partnership that draws on the lab’s unique capabilities to create a paradigm change in drug development
— Bill Goldstein, Director of LLNL

 

what we do

 

ATOM develops, tests, and validates a multidisciplinary approach to drug discovery in which modern science, technology and engineering, supercomputing simulations, data science, and artificial intelligence are highly integrated into a single drug-discovery team approach that can ultimately be shared with the drug discovery community at large and applied to other disease areas.

ATOM transforming drug discovery.png

The consortium will achieve its goals by building new tools, models, and processes that it intends to make broadly available as a shared resource to accelerate drug discovery. Scientific understanding and vast amounts of data gathered from decades of research will be used by the consortium in hopes that the information will be leveraged to find solutions for cancer patients. 

The ATOM team will combine publicly available data, the data provided by GSK, and that of future consortium members, to generate new dynamic models that can better predict how molecules will behave in the body, potentially bringing new drugs to patients faster. In this effort, Lawrence Livermore National Laboratory will contribute its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning, and algorithm development. 


We need to get better medicines to patients faster. This project aims to do that.
— Alan Ashworth, President of UCSF Helen Diller Family Comprehensive Cancer Center

ATOM Leadership

 

Joint Research Committee (JRC) & Leadership Team

 
Jim Brase.jpg

Jim Brase

ATOM Chief Technical Officer & Interim Co-Lead
Deputy Associate Director for Computation
Lawrence Livermore National Laboratory

 
Stacie Calad-Thomson.jpg

Stacie Calad-Thomson, Ph.D.

ATOM Chief Operating Officer & Interim Co-Lead

 
Tom Rush 2.jpg

Tom Rush, Ph.D.

ATOM Chief Scientific Officer & Interim Co-Lead
Senior Director and Head of Biology Automation
GSK

 
Michelle Arkin.jpg

Michelle Arkin, Ph.D.

ATOM JRC Member
Associate Professor, Department of Pharmaceutical Chemistry
UCSF

 
Amy Gryshuk.jpg

Amy Gryshuk, Ph.D.

ATOM Deputy Operating Officer

 
Dwight Nissley.png

Dwight Nissley, Ph.D.

ATOM JRC Member
Director, Cancer Research Technology Program
Frederick National Laboratory for Cancer Research

Governing Board

 
John Baldoni.jpg

John Baldoni

ATOM Founder and Governing Board Co-Chair
Senior Vice President for R&D
GSK

 
John MacWilliams.jpg

John MacWilliams

ATOM Governing Board Co-Chair
Senior Advisor to the Director
Lawrence Livermore National Laboratory

 
Alan Ashworth.jpg

Alan Ashworth, Ph.D., FRS

President
UCSF Helen Diller Family Comprehensive Cancer Center

 
Ethan Dmitrovsky 2.jpg

Ethan Dmitrovsky, M.D.

Laboratory Director
Frederick National Laboratory for Cancer Research

 
Patricia Falcone 3.jpg

Patricia Falcone, Ph.D.

Deputy Director for Science and Technology
Lawrence Livermore National Laboratory

 
Barry Selick.png

Barry Selick, Ph.D.

Vice Chancellor, Business Development, Innovation, and Partnerships
UCSF

 
Eric Stahlberg.png

Eric Stahlberg, Ph.D.

Director, High Performance Computing
Frederick National Laboratory for Cancer Research

 

Membership

 

Benefits of Membership

ATOM is actively seeking additional partnerships with organizations who share in our vision  

 

Member benefits include access to:
1.    Algorithms and generated data for a member-benefit period
2.    Training and capability development for employees
3.    Best-in-class computational resources
4.    Expertise of the group and leaders in their industries
5.    Unique collaboration and incubation environment
6.    Workflow for internal drug discovery and commercialization


UCSF scientists and clinicians have long been leaders in drug discovery, therapeutics, and cancer biology with the UCSF Helen Diller Family Comprehensive Care Center among the top-ranked cancer institutes in the country. Our role with ATOM is therefore in lock step with UCSF’s mission of advancing health worldwide.
— Sam Hawgood, MBBS, UCSF Chancellor

 

Consortium Members

 
GSK logo.jpg

GSK will provide chemical and in vitro biological data for more than 2 million compounds from its historic and current screening collection, as well as preclinical and clinical information on 500 molecules that have failed in development but provide data that could help advance new, successful compounds. GSK also expects to offer expertise in drug discovery and development, computational chemistry, and biology.

 

Lawrence Livermore National Laboratory will contribute its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning, and algorithm development. More broadly, by applying high-performance computing to the ambitious problem of cancer therapy, the Department of Energy and National Nuclear Security Administration hopes to accelerate technologies vital to its core missions.

llnl simple logo.png
 
fnlcr_nci-subtext_4line-2.jpg

Frederick National Laboratory, on behalf of the National Cancer Institute, will contribute scientific expertise in precision oncology, computational chemistry and cancer biology, as well as support for open sharing of data sets and predictive modeling and simulation tools. 

 

UC San Francisco will provide expertise from a long-history of innovation in medicine and drug discovery combined with its strengths in cancer and translation of technologies and therapeutics to improve the lives of patients.

UCSF full logo.png
 

We must do all that we can to reduce the time it takes to get medicines to patients. GSK is working to set a precedent with pharmaceutical companies by sharing data on failed compounds.
— John Baldoni, Senior Vice President R&D at GSK

 

contact

 

The ATOM Consortium is actively seeking additional partnerships with qualified pharma, biotech, technology, academic, government, and other organizations.

 
 
 

ATOM Headquarters

499 Illinois Street
4th floor
San Francisco, CA 94158

info@atomscience.org

 

Connect with us

If you would like to learn more about ATOM, fill out the form below and one of our team members will get back to you.

Name *
Name

Job Opportunities

 

Postdoctoral Researcher:

Pathway, Cell & Tumor Modeling

ATOM is seeking a PhD level scientist with experience in pathway, whole cell and/or tumor level modeling. The incumbant will be part of a larger cross-functional consortium team at the ATOM facility, and together this team will be responsible for building and utilizing multi-scale mechanistic models to predict the pharmacokinetics, efficacy & safety liabilities (on/off target) of small molecule therapeutic candidates in healthy and diseased human systems. The models are intended to be used in virtual screens, integrated into multi-parameter active-learning based drug development workflows, and utilized in the ongoing development and validation of a quantitative pharmacology model for individual cancer patients.

 

Postdoctoral Researcher:

Quantitative Pharmacology

ATOM is seeking a Quantitative Pharmacologist with experience in clinical PKPD simulations and/or translating preclinical pharmacokinetics, pharmacodynamics and safety responses to humans. The incumbent will be part of a larger cross-functional consortium team at the ATOM facility, and together this team will be responsible for creating and maintaining quantitative models that will keep the execution teams focused on the most critical set of assays, predictions and design criteria during the accelerated Discovery effort.


Postdoctoral Researcher:

Computational Chemistry & Drug Discovery

ATOM is seeking a Computational Chemist or Scientist with experience in data-driven, structure-based or mechanistic computational modeling techniques to identify and optimize small molecule drug candidates. The incumbent will be part of a larger cross-functional consortium team at the ATOM facility that will be responsible for developing and employing computational approaches that will significantly accelerate the identification and optimization of small molecule leads in silico.


Postdoctoral Researcher:

Computational ADME/Tox

ATOM is seeking a  a Computational Scientist with experience in computational modeling of the pharmacokinetics and/or toxicology of human therapeutics. The incumbent will be part of a larger cross-functional consortium team at the ATOM facility, and together this team will be responsible for building and utilizing multi-scale mechanistic and data-driven models to predict the pharmacokinetics, efficacy & safety liabilities (on/off target) of small molecule therapeutic candidates in healthy and diseased human systems. The models are intended to be used in virtual screens, integrated into multi-parameter active-learning based drug development workflows, and utilized in the ongoing development and validation of a quantitative pharmacology model for individual cancer patients.


ATOM in the News

 
 
 

Media Contacts

 

Laura Kurtzman
Senior Public Information Officer
UCSF
415-476-3163
laura.kurtzman@ucsf.edu

 

Jeremy Thomas
Public Information Officer
Lawrence Livermore National Laboratory
925-423-7602
925-422-5539

 

Frank Blanchard
Director, Public Affairs and Communications
Frederick National Laboratory for Cancer Research
301-846-1893
frank.blanchard@nih.gov

 

Mary Anne Rhyne
Director, Corporate Communications
GSK
919-483-0492
mary.a.rhyne@gsk.com